Introduction
DNA topoisomerases (topos) alleviate the topological constraints associated with the double-helical structure of DNA during vital cellular processes, including DNA replication, transcription, chromosome segregation and recombination. [1] [2] [3] Mammalian topo II consists of two isoforms, topo IIa (M r 170 kDa) and topo IIb (M r 180 kDa). Although both enzymes are highly homologous and catalyze similar biochemical reactions, they are genetically distinct and exhibit different patterns of expression and cellular distribution. [2] [3] [4] [5] Although expression of topo IIa is cell cycle-dependent, 6 topo IIb levels remain unchanged during cell cycle progression 6 and are maximal in terminally differentiated tissues. 4 This distinct difference in expression suggests that these two enzymes may play separate roles in cellular processes that require topological changes in the DNA molecule. It has been suggested that topo IIa may be important for DNA replication, whereas topo IIb may be involved in cellular differentiation. 5 Although the role of topo IIa in cell proliferation has been extensively studied, the precise functional role of topo IIb during cell growth and/or differentiation remains unclear.
Recent studies have established a critical role for topo IIb during different stages of neuronal development and differentiation. [7] [8] [9] Mice lacking topo IIb die shortly after birth owing to defects in motor axon growth. It has been suggested that topo IIb may be involved in gene expression and chromatin remodeling in non-proliferating, differentiated cells, for example, neurons, that do not express topo IIa. A potential role for topo IIb in differentiation of hematopoietic cells has also been proposed based on studies demonstrating altered expression of this protein following differentiation. Kaufmann et al., evaluating the role of topos during granulocytic maturation of the myeloblastic leukemia (FAB M2) cell line, HL-60, induced with dimethyl sulfoxide showed that both protein levels and activity of topo I and topo II were reduced in differentiated cells. 10, 11 In contrast, our studies evaluating the role of topos during all-trans retinoic acid (ATRA)-induced granulocytic differentiation of HL-60 cells revealed that whereas expression of topo I protein was unaffected by ATRA treatment, expression of topo IIa and b proteins, particularly the topo IIb isoform, was increased. 12 Enhanced post-translational phosphorylation of these isozymes paralleled the increases in protein levels of topo IIa and b. 12 Retinoid-induced changes in the levels and/or phosphorylation of topo II have also been reported by Chresta et al. 13 and by Kim and Lotan. 14 Retinoids, the natural and synthetic derivatives of vitamin A, play a key role in myeloid differentiation [15] [16] [17] and preferentially stimulate granulopoiesis by binding to nuclear retinoic acid receptors (RAR a, b or g) and rexinoid receptors (RXR a, b or g). The retinoic acid-RAR-RXR heterodimer complex transcriptionally activates target genes regulated by retinoic acid response elements (RARE) in their promoter region. RARs/RXRs modulate transcription by interacting with cofactors, both corepressors and co-activators, in a multiprotein complex. [18] [19] [20] The presence of histone deacetylases in the corepressor complex, and of histone acetylases and proteins exhibiting DNA helicase activity in the co-activator complex, suggests that alterations in chromatin structure and unwinding of DNA are essential for transcriptional activation of genes from RARE. 16 Within this context, DNA topos could play an important role in myeloid differentiation by locally altering DNA topology to facilitate gene transcription.
Our previous study 12 demonstrating a potential role for the topo IIa and b isozyme in retinoic acid-induced differentiation of HL-60 cells, prompted us to determine whether these two enzymes are involved in ATRA-induced differentiation. In this study, we tested the functional role of these two isozymes by determining the effect of targeted downregulation of topo IIa and b with specific small interfering RNAs (si-RNAs) on ATRAinduced differentiation in several myeloid leukemia cell lines. Our results indicate that topo IIa does not influence differentiation, cell growth or survival of ATRA-treated cells. However, topo IIb is required for maintaining viability of ATRA-differentiated myeloid leukemia cells. Studies to examine the mechanism by which topo IIb serves as a survival signal during granulocytic differentiation revealed that deficiency of topo IIb in the HL-60 cell line leads to downregulation of the antioxidant protein, peroxiredoxin 2 (PRDX2), 21 thereby resulting in the accumulation of reactive oxygen species (ROS) following treatment with ATRA and subsequent activation of the apoptotic pathway. 
Materials and methods

Materials
Cell culture and treatment of cells
The parental HL-60 cells 12 were obtained from the American Type Culture Collection (Rockville, MD, USA). Cultures of HL60, KG1 and NB4 cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine (MA Bioproducts, Gaithersburg, MD, USA). Amsacrine-resistant HL-60 (AMSA-R) cells 22 were obtained from Dr Leonard Zwelling, MD Anderson Cancer Center, Houston, TX, USA and maintained in culture similar to the parental HL-60 cells. The AP-1060 cells were maintained in IMDM supplemented with 10% FBS and 2 mM Lglutamine and 5% conditioned medium, which was prepared from 5637 cells cultured in RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine as described earlier. 23 All cell lines were maintained during subculture or for experimental protocols at 371C in a humidified 5% CO 2 plus 95% air atmosphere. Cells were treated with 1 mM ATRA and/or 0.1-0.25 mM ICRF-193 continuously for 96 h during which time aliquots were retrieved at 24 h intervals for analysis of proliferation, differentiation, apoptosis and cell survival. 12 Alternatively, cells were treated with ATRA and/or ICRF-193 for 48-96 h, washed and reincubated in drug-free medium for 72-168 h before analysis for apoptosis and ROS.
Generation of stable cell lines transfected with topo II isoform-targeted si-RNA or topo IIb cDNA or PRDX2 cDNA
The si-RNAs targeted to topo IIa (si-topo IIa), topo IIb (si-topo IIb) and green fluorescent protein (si-GFP) as a control were transcribed from a modified pBabe-puromycin retroviral vector. 24 26 in which the full-length topo IIb or PRDX2 cDNA, respectively, was cloned. Transfection with the empty vector served as a control. The topo IIb-transfected cells were subsequently selected in 1 mg/ml G418 and by fluorescenceactivated cell sorting.
Differentiation, apoptosis and cell survival
Differentiation was determined by measuring the ability of cells to reduce nitroblue tetrazolium, as described earlier. 12 Apoptosis was determined by fluorescence microscopy in cells stained with Hoechst 33342 (70 mg/ml) and propidium iodide (100 mg/ ml) at 371C for 15 min. 27 Cell survival was determined by a softagar colony assay. 28 
Cell lysis and Western blotting
Aliquots of cell lysates in RIPA buffer 26 containing equivalent amounts of protein (10-50 mg) or cell number were electrophoresed on Tris acetate or Bis-Tris gels (InVitrogen Corp., Carlsbad, CA, USA). The separated proteins were transferred to PVDF membrane (Bio-Rad Laboratories, Hercules, CA, USA) and subjected to Western blot analysis with specific antibodies.
4,28
Analysis of ROS
The fluorescent dye, dihydroethidium, 29 was used to probe for the accumulation of ROS in untreated or ATRA-treated cells. Dihydroethidium exhibits a blue fluorescence in the cytosol, but once the dye is oxidized to ethidium, it intercalates with the cell DNA and emits a bright red fluorescence. Briefly, cells were incubated in the absence or presence of 1 mM ATRA for 72 h and subsequently incubated with 20 mM dihydroethidium for 45-90 min. The emitted red fluorescence was analyzed 30 in a Beckman-Coulter Epics flow cytometer.
Results
Inhibition of topo IIb activity in myeloid leukemia cell lines with a topo IIb-specific catalytic inhibitor, ICRF-193, enhances ATRA-induced differentiation and cytotoxicity Our previous study implicated that the topo II isozymes, topo IIa and/or topo IIb may be involved in ATRA-induced differentia- 
Reduced expression of topo IIb in HL-60 cells leads to enhanced ATRA-induced differentiation and apoptosis
The data with ICRF-193 suggested that topo IIb was required for maintaining survival of differentiated cells. To confirm the role of topo IIb as a survival signal and to determine the function of topo IIa during ATRA-induced differentiation, we employed a molecular approach involving stable downregulation of topo IIa or topo IIb expression with targeted si-RNAs. The si-RNA to topo IIa (si-topo IIa) was directed to the 3 0 -untranslated region, whereas two siRNAs to different coding regions of topo IIb (si-topo IIb and si-topo IIb-L) were employed. Transfection of these three siRNAs in the HL-60 cell line led to significant downregulation of topo IIa and topo IIb protein. In si-topo IIatransfected HL-60 cells (HL-60/si-topo IIa), topo IIa protein was downregulated B32-fold. In si-topo IIb-or si-topo IIb-Ltransfected HL-60 cells (HL-60/si-topo IIb or HL-60/si-topo IIb-L, respectively), topo IIb protein was downregulated B32-or eightfold, respectively (Supplementary Information; Supplementary Figure 1a -c). HL-60 cells transfected with an siRNA to GFP (HL-60/si-GFP) served as a control. In addition to these cell lines, an amsacrine-resistant HL-60 cell line (HL-60/AMSA-R), which is deficient in topo IIb mRNA and protein, 22 was also studied. Treatment of HL-60/si-GFP, HL-60/si-topo IIa, HL-60/sitopo IIb, HL-60/si-topo IIb-L or HL-60/AMSA-R cells with 1 mM ATRA revealed that ATRA-induced differentiation at 48 and 96 h in si-GFP or si-topo IIa cells was significantly lower (Po0.001) than in similarly treated topo IIb-deficient cells, HL-60/si-topo IIb, HL-60/si-topo IIb-L or HL-60/AMSA-R (Figure 2a) . As HL-60/ si-GFP and HL-60/si-topo IIa cells continue to differentiate after 96 h, the increased differentiation observed at 48 and 96 h in topo IIb-deficient cells was likely owing to acceleration of the differentiation process. Determination of proliferation in these cells revealed that following differentiation with ATRA, cell Figure 2b ). This observation suggested that si-topo IIb-transfected cells were undergoing cell death following treatment with ATRA, which was confirmed in cell survival (determined by colony formation in soft agar) and apoptosis studies. The number of colonies formed in ATRA-treated HL-60/si-topo IIb cells was only 10% of that observed in the untreated control, which is significantly lower (P ¼ 0.002) than the 60-70% colony formation observed in ATRA-treated HL-60/si-GFP or HL-60/si-topo IIa cells, compared to the corresponding untreated control (Figure 2c ). 21 we chose to focus on the role of this gene in the apoptotic pathway induced by ATRA in topo IIb-deficient cells. Expression of PRDX2 protein, as determined by Western blot analysis, was significantly reduced in all topo IIb-deficient cells. PRDX2, which was clearly visible in cell extracts of WT HL-60, HL-60/si-GFP and HL-60/si-topo IIa cells, was almost undetectable in cell extracts of HL-60/si-topo IIb, HL-60/si-topo IIb-L and HL-60/AMSA-R cells (Figure 5a and b) . Further, expression of PRDX2 was not altered following ATRA treatment (Figure 5a ).
Downregulation of PRDX2 protein in topo IIb-deficient HL-60 cells correlates with the accumulation of ROS following ATRA-induced differentiation
As PRDX2 has been shown to inhibit apoptosis by scavenging ROS, including hydroperoxides, the absence of this protein could promote apoptosis via accumulation of ROS that might be generated as a signaling molecule during ATRA-induced differentiation. Therefore, we determined whether ATRA treatment of topo IIb-and PRDX2-deficient HL-60 cells leads to accumulation of ROS. As shown in Figure 6 , there was no discernible shift in the fluorescence peak of ATRA-treated HL-60/si-GFP cells compared to untreated HL-60/si-GFP cells. However, a distinct and significant shift in the fluorescence peak of ATRA-treated compared to untreated HL-60/si-topo IIb, HL-60/si-topo IIb-L and HL-60/AMSA-R cells was observed. The 
Discussion
Several studies have implicated a role for topo IIb in cellular differentiation, particularly in differentiation of neuronal and blood cells. 5, [7] [8] [9] 12 This enzyme is abundantly expressed in nonproliferating differentiated tissues, 4 which is in contrast to the preferential expression of the topo IIa isozyme in proliferating cells. [1] [2] [3] The functional role of topo IIb in embryonic neuronal development has been clearly established. 8 It has been demonstrated that targeted deletion of the topo IIb gene in mice leads to defects in neuronal development and perinatal death. Furthermore, induction of topo IIb is observed in subtypes of neuronal cells undergoing differentiation at various stages of development. 8 The potential involvement of topo IIb, as well as topo IIa, in myeloid differentiation has also been proposed based on altered expression of these proteins following differentiation of myeloid precursor cells. [10] [11] [12] [13] In this report, we show that targeted downregulation of topo IIb, but not topo IIa, in HL-60 cells accelerates differentiation by ATRA and subsequently leads to apoptosis of these differentiated cells. Interestingly, these topo IIb-deficient cells are also deficient in PRDX2, an anti-oxidant protein that has been reported to inhibit apoptosis by locally scavenging ROS, that is, hydrogen peroxide. Consistent with this mechanism, reduced presence of PRDX2 in topo IIb-deficient cells correlates with accumulation of ROS upon stimulation with ATRA. Thus, our study defines a novel role for topo IIb as a survival signal during granulocytic maturation of myeloid cells. Our studies demonstrating ATRA-induced apoptosis in several topo IIb-deficient cell lines that were generated by using different experimental approaches to downregulate topo IIb (siRNAs directed to different regions of topo IIb or selection for resistant clones to the topo IIb targeting drug, amsacrine) strongly suggest that the apoptotic response of these cells following ATRA-induced differentiation was specific to reduced expression of topo IIb and was not due to altered expression of some other gene product. Consistent with this finding, the magnitude of the apoptotic response correlated with the level of downregulation of topo IIb protein in topo IIb siRNA-transfected cells. Thus, in HL-60/si-topo IIb cells, in which topo IIb protein was downregulated 32-fold, ATRA led to a 10-fold increase in apoptosis compared to control HL-60/si-GFP cells. However, in the HL-60/si-topo IIb-L and KG1/si-topo IIb cells in which topo IIb protein was downregulated four-to eightfold, ATRA treatment increased apoptosis by twofold compared to the control si-GFP cells. In the HL-60/AMSA-R cells, in which topo IIb protein was undetectable, the increase in ATRA-induced apoptosis was only twofold relative to the WT cell line expressing significantly higher levels of topo IIb. Although colony formation in soft agar was o10% following ATRAinduced differentiation in the HL-60/si-topoIIb and HL-60/ AMSA-R cells, the lower apoptotic response in ATRA-treated HL-60/AMSA-R cells could be related to multi-factorial changes associated with prolonged drug exposure during selection for amsacrine resistance. Interestingly, similar potentiation of ATRA-induced apoptosis was also observed when topo IIb activity was inhibited by non-toxic doses of the topo IIb-specific catalytic inhibitor, ICRF-193, in several myeloid leukemia cell lines, including the APL cell line, AP-1060, which was derived from a patient resistant to ATRA treatment. However, the most direct evidence for the specific role of topo IIb in the ATRAinduced apoptotic response was obtained from studies demonstrating rescue of viability in ATRA-treated HL-60/AMSA-R cells engineered for overexpression of topo IIb. Collectively, these data underscore the importance of topo IIb in maintaining cell viability during granulocytic differentiation.
As reduced expression of topo IIb did not affect cell proliferation in the absence of ATRA, topo IIb protein levels seem to be important only for maintaining cellular viability during differentiation or growth arrest. This is apparent in the decreased survival only of ATRA-treated topo IIb-deficient cells. As expected, the topo IIb-deficient cell lines did not exhibit retarded growth characteristics, as the topo IIa isozyme predicted to be involved in DNA replication and chromosome segregation was not downregulated. The topo IIa-deficient cells, despite expressing significantly lower levels (B32-fold) of the protein relative to WT or HL-60/si-GFP cells, did not exhibit altered growth characteristics, which might have been expected because of the role of topo IIa in cell proliferation. This finding suggests that the topo IIa isozyme cannot substitute for topo IIb in promoting survival of differentiated myeloid leukemia cells, whereas topo IIb could substitute for the topo IIa isozyme in regulating cell growth.
It has been proposed that during neuronal differentiation topo IIb may directly or indirectly modulate expression of a subset of neuronal genes. 8, 9 Several topo IIb-specific genes including the RELN gene have been identified as potential candidates. 8 In this study, we found that deficiency of topo IIb led to downregulation of PRDX2 mRNA and protein in all three topo IIbdeficient HL-60 cells, HL-60/si-topo IIb, HL-60/si-topo IIb-L and HL-60/AMSA-R, suggesting that topo IIb might regulate expression of this gene. Although the molecular mechanism by which topo IIb regulates gene transcription is not clearly understood, it has been suggested that topo IIb functions by modifying the chromatin structures of specific chromosomal regions, via condensation or decondensation to different degrees of compaction, which is required for activating transcription of genes located within this region. 9 Alternatively, topo IIb in association with other proteins could regulate transcription of specific genes. A similar mechanism for regulation of myeloid differentiation by topo IIb can be envisioned. Topo IIb could alter DNA topology in distinct chromosomal regions that have acquired specific topological organizations during commitment of the immature cells to differentiation, thereby leading to activation of transcription of myeloid-specific genes. Thus, identification of topo IIb-specific genes that are altered either in control or ATRA-treated topo IIb-deficient cells relative to topo IIb-expressing cells will provide insights into the mechanisms by which topo IIb regulates differentiation of myeloid cells.
In summary, these studies are the first to demonstrate a role for topo IIb in the differentiation of myeloblastic leukemia cells, specifically in maintaining survival of these cells during granulocytic maturation. Further, we identify PRDX2 as a likely downstream target that is required for survival of cells during differentiation. In this role, PRDX2 may act by locally reducing hydroperoxides that might be generated physiologically as signaling molecules upon stimulation with ATRA. Alternatively, PRDX2 may be involved in reducing and thereby regulating the activity of key enzyme intermediates, as has been demonstrated for the reduction and activation of the phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase by PRDX2 during growth factor signaling via the phoaphatidylinositol 3,4,5-trisphosphate (PIP 3 ) pathway. 30 Thus, by targeting topo IIb and/or PRDX2 with small molecule inhibitors, the efficacy of ATRA-based differentiation therapy for the treatment of myeloid leukemias can be potentially improved.
